Migraines affect one in eight men and women and are marked in World Health Organization’s top twenty top most disabling lifetime conditions. The severe headaches that go together with nausea, visual disturbance and sensitivity to light can occupy up to three days to pass.
In new study researchers have identified a migraine gene that could raise hope for new drug to pinch the crippling headaches. Present medication is not effective or suitable for all patients but the newest research could make the condition more tolerable for millions.
The team of researchers led by experts from the Wellcome Trust Sanger Institute, in Cambridge, evaluated the DNA of thousands of migraine patients with the healthy people. This emphasized a genetic flaw that seems to increase the chances of the condition by permitting glutamate which is substance to convey messages in the brain, to build up in the intersections between brain cells.
Medication that prevents glutamate from collecting could stop migraines, reports the journal Nature Genetics. Though past study has recognized gene connected with rare form of migraine, never before has one behind the most widespread form of the condition been established.
This is for the first time that they have been able to examine genomes of thousands of people and find hereditary evidences to understand ordinary migraine, explained Dr Aarno Palotie from the Sanger Institute. The study could pave new ways to understand normal individuals’ disease.
The study will look in depth at the biology of the disease and how the modification can exert its effects, said Professor Christian Kubisch, of the University of Ulm, Germany.